Find clinical trials for Lymphoma in Nashville, TN
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Lymphoma trials near Nashville, TN, USA:
of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing)....
Phase 1
Nashville, Tennessee, United States and 6 other locations
patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option.ARV-3...
Phase 1
Nashville, Tennessee, United States and 15 other locations
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic...
Phase 2
Nashville, Tennessee, United States and 71 other locations
A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin's Lymphoma...
Phase 1, Phase 2
Nashville, Tennessee, United States and 3 other locations
and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma...
Phase 1, Phase 2
Nashville, Tennessee, United States and 75 other locations
treatment of advanced classical Hodgkin lymphoma(HL)...
Phase 3
Nashville, Tennessee, United States and 215 other locations
in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus za...
Phase 3
Nashville, Tennessee, United States and 139 other locations
by the intravenous (IV) route to participants with solid tumors or lymphomas.The main goals of this study are to:* Find the recommended dose...
Phase 1, Phase 2
Nashville, Tennessee, United States and 9 other locations
Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The secondary objectives are to characterize t...
Phase 1
Nashville, Tennessee, United States and 4 other locations
(firi-cel), a CD22-directed autologous Chimeric Antigen Receptor (CAR) T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma...
Phase 2
Nashville, Tennessee, United States and 30 other locations
Clinical trials
Research sites
Resources
Legal